Mirum Pharmaceuticals (NASDAQ:MIRM) SVP Jolanda Howe Sells 4,732 Shares

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) SVP Jolanda Howe sold 4,732 shares of the company’s stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $91.98, for a total transaction of $435,249.36. Following the sale, the senior vice president owned 8,429 shares of the company’s stock, valued at approximately $775,299.42. The trade was a 35.95% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Jolanda Howe also recently made the following trade(s):

• On Monday, February 2nd, Jolanda Howe sold 968 shares of Mirum Pharmaceuticals stock. The shares were sold at an average price of $103.30, for a total value of $99,994.40.
• On Monday, January 26th, Jolanda Howe sold 842 shares of Mirum Pharmaceuticals stock. The stock was sold at an average price of $96.19, for a total value of $80,991.98.
• On Thursday, January 22nd, Jolanda Howe sold 926 shares of Mirum Pharmaceuticals stock. The stock was sold at an average price of $93.33, for a total value of $86,423.58.

Mirum Pharmaceuticals Price Performance

Shares of NASDAQ MIRM traded up $3.91 during midday trading on Tuesday, reaching $96.55. The company had a trading volume of 865,362 shares, compared to its average volume of 830,531. Mirum Pharmaceuticals, Inc. has a one year low of $36.88 and a one year high of $109.28. The firm’s fifty day moving average price is $95.73 and its 200-day moving average price is $80.84. The company has a current ratio of 2.67, a quick ratio of 2.55 and a debt-to-equity ratio of 0.98.

Mirum Pharmaceuticals (NASDAQ:MIRM) last posted its quarterly earnings results on Wednesday, February 25th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.02 by ($0.13). The company had revenue of $148.93 million for the quarter, compared to the consensus estimate of $141.78 million. Mirum Pharmaceuticals had a negative return on equity of 8.53% and a negative net margin of 4.48%.Mirum Pharmaceuticals’s revenue was up 49.8% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.00 earnings per share. Equities analysts predict that Mirum Pharmaceuticals, Inc. will post -1.43 earnings per share for the current fiscal year.

Analyst Ratings Changes

MIRM has been the topic of several analyst reports. Robert W. Baird lifted their target price on shares of Mirum Pharmaceuticals from $80.00 to $88.00 and gave the stock an “outperform” rating in a research note on Monday, December 8th. TD Cowen increased their price target on shares of Mirum Pharmaceuticals from $115.00 to $117.00 and gave the company a “buy” rating in a research report on Thursday, February 26th. Cantor Fitzgerald reissued an “overweight” rating and issued a $130.00 price target on shares of Mirum Pharmaceuticals in a report on Monday, December 8th. Citigroup restated an “outperform” rating on shares of Mirum Pharmaceuticals in a research report on Friday, December 19th. Finally, HC Wainwright upped their price objective on shares of Mirum Pharmaceuticals from $102.00 to $130.00 and gave the company a “buy” rating in a research note on Monday, January 26th. One analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $117.00.

Institutional Investors Weigh In On Mirum Pharmaceuticals

Hedge funds have recently made changes to their positions in the company. Cullen Frost Bankers Inc. bought a new stake in shares of Mirum Pharmaceuticals during the 4th quarter valued at $30,000. MCF Advisors LLC increased its position in shares of Mirum Pharmaceuticals by 76.4% during the third quarter. MCF Advisors LLC now owns 427 shares of the company’s stock valued at $31,000 after acquiring an additional 185 shares in the last quarter. Eurizon Capital SGR S.p.A. purchased a new position in shares of Mirum Pharmaceuticals in the fourth quarter worth $32,000. CIBC Private Wealth Group LLC purchased a new position in Mirum Pharmaceuticals in the 4th quarter worth about $32,000. Finally, Quantbot Technologies LP bought a new position in Mirum Pharmaceuticals during the third quarter valued at approximately $33,000.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.